Subsequent studies in murine models showed the ability of CD40 stimulation to achieve TME remodeling as a monotherapy, and increased tumor control was achieved when CD40 stimulation and anti-CTLA-4 and anti-PD1 were used in combination with chemotherapy. This evidence concerns the gene CD40 and neoplasm.